Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx UNESCO oznámeno xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx xxx xxx 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx.

X xxxxx xxxxxx Xxxxxxx X vyslovil xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx změn Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx s článkem 34 odst. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. června 2024 x nahradilo Xxxxxxx X pro xxx 2023, platnou od 1. xxxxx 2023, xxxxx vstoupila v xxxxxxxx xxx Českou xxxxxxxxx dne 22. xxxxxx 2023 x xxxx vyhlášena pod č. 32/2023 Sb. m. s.

Xxxxxxxx znění Xxxxxxx X xxx xxx 2024 x xxxx xxxxxxx do českého xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x z. XXXx. Xxxxxx, Ph.D., XX.X., x. r.

vrchní xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Xxxxxxx xxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xx povinný Xxxxxxxxxxx xxxxxxxx x xxxxx Světového xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx rozsáhlém xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou agenturou (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx text Xxxxxxx xxxxxxxxxx xxxxx x metod xxxx xxxxxxxxx WADA a xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx jakýchkoliv xxxxxxxxxxxxx xxxx anglickým x francouzským xxxxxx xxxxxxxxx xxxxx v xxxxxxxxxx.

Xxxx jsou xxxxxxx xxxxxxx xxxxx xxxxxxxxx x xxxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Při xxxxxxx

Xxxxx XXXX xxx xxxx xxxxx xxxxxxxxxxx jiné xxxxxx, xx xxxxxx Xxx soutěži v xxxxxx xxxxxxx xxxxxxxxxxx xxxxx xxxx xxxxxxx (xx 23:59 hodin) x den xxxxxxxxxxxxx Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, xx do konce Xxxxxxx x xxxxxxx xxxxxx Vzorku.

Zakázané xxxxx

Xx xxxxxxx, xx xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Při xxxxxxx i Xxxx xxxxxx, jak xx xxxxxxxxxx x Kodexu.

Specifické x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Zakázané xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx xxxx xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx a xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, pokud xxxx x Xxxxxxx xxxxxxxxx označena xxxx Xxxxxxxxxx metoda.“ Xxxxx xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx a Xxxxxxxxxx xxxxxx uvedené x xxxxxx 4.2.2 xx xxxxxx xxx xxxxxx způsobem xxxxxxxxxx xx méně důležité xxxx xxxx xxxxxxxxxx xxx xxxx xxxxxxxxx xxxxx xxxx xxxxxx. Xxx spíše o xxxxx x xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx xxxxx xxx xx xxxxxxxx xxxxxxxxxxx výkonu.“

Návykové xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx jsou jako xxxxxx označeny x xxxxxx jejich xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx rámec sportu. Xxxx Xxxxxxxx xxxxx xxxx označovány tyto xxxxx: kokain, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Jakákoliv xxxxxxxxxxxxxx xxxxx, xx xxxxxx se nevztahuje xxxxx z následujících xxxxxx Xxxxxxx a xxxxx není x xxxxxxxx době xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx použití x xxxx (xxxx. léčiva x předklinickém xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx vývoj byl xxxxxxx, syntetické xxxxx, xxxxx schválené xxxxx xxx xxxxxxxxxxx použití), xx zakázána xxxxx.

Xxxx xxxxx xxxxxxxx mnoho xxxxxxx xxxxx, mimo xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x xxxxxxxxxx xxxxxxxxx (xxxx. Reldesemtiv x Xxxxxxxxxx).

X1 XXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)

Xxx xxxxxxxxx xxxxxx, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol)
•	1-androsteron (3ɑ-hydroxy-5a-androst-1-en-17-on)		•	gestrinon
•	1-epiandrosteron (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on)		•	mesterolon
•	4-androstenediol (androst-4-en-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on)
•	4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on)		•	metenolon
•	5-androstenedion (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on)
•	7-keto-DHEA		•	metylklostebol
•	11ß-metyl-19-nortestosteron		•	metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)
•	17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on)
•	Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-hydroxy-5ɑ-androstan-3-on)		•	nandrolon (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol)		•	norboleton
•	androstenedion (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-hydroxy-5β-androstan-3-on)		•	tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-hydroxyestr-4,9,11-trien-3-on)
•	fluoxymesteron		•	trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT)

a další xxxxx x podobnou xxxxxxxxx strukturou nebo xxxxxxxxx biologickými xxxxxx.

X1.2. XXXXXXX ANABOLICKÉ XXXXX

Xxxx xxxx včetně:

Clenbuterol, xxxxxxxxxxxx, xxxxxxxxxx, selektivní xxxxxxxxxx xxxxxxxxxxxxx receptorů [XXXX, xxxx. andarin, xxxxxxxxx (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, S-23 x XX-11], xxxxxxx a xxxxxxxxxx.

X2 PEPTIDOVÉ XXXXXXX, XXXXXXX FAKTORY, XXXXXXXX XXXXX X XXXXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X MIMO SOUTĚŽ)

Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.

X2.1. XXXXXXXXXXXXX (EPO) X XXXXX OVLIVŇUJÍCÍ XXXXXXXXXXX

Xxxx jiné včetně:

S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (dEPO); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx xx XXX, [xxxx. EPO-Fc, metoxypolyetylenglykol-epoetin xxxx (CERA)]; EPO- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (GSK1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (AKB-6548); xxxxx.

X2.1.3 Xxxxxxxxxx GATA, xxxx. X-11706.

X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx růstového faktoru xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Agonisté xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. xxxxxx XXX; xxxxxxxxxxxxx XXX (XXXX).

X2.2. XXXXXXXXX HORMONY X XXXXXX UVOLŇUJÍCÍ XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx testosteron x xxxx, xxxx xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (XX),

• xxxxxxxxxxxx xxxxxx (XX),

• hormon xxxxxxxxxx gonadotropin (XxXX, xxxxxxxxxxx) x xxxx xxxxxxxxxxx xxxxxxx (např. xxxxxxxxx, xxxxxxxxxx, goserelin, xxxxxxxxx, leuprorelin, xxxxxxxxx x triptorelin),

 • xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx hormon (XX), jeho analogy x fragmenty, mimo xxxx včetně:

• analogy xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x xXX 176–191.

X2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, xxxx xxxx xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx hormon (XXXX) x xxxx analogy, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx x tesamorelin,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x xxxxxx xxxxxxxx [xxxx. anamorelin, xxxxxxxxxxxx, xxxxxxxxxx (MK-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx a xxxxxxxxxxx],

• xxxxxxx xxxxxxxxxx XX (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5 a XXXX-6].

X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX RŮSTOVÝCH XXXXXXX

Xxxx jiné xxxxxx:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (XXX)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, mecasermin) x xxxx xxxxxxx

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• růstový xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX)

• thymosin-β4 x xxxx deriváty, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF)

a xxxxx růstové xxxxxxx xxxx xxxxxxxxxx růstových xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx nebo vazech, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (PŘI SOUTĚŽI X MIMO SOUTĚŽ)

Všechny xxxxxxxx látky x xxxx xxxxx jsou Xxxxxxxxxx látky.

Všichni xxxxxxxxxx x xxxxxxxxxxxx beta-2 xxxxxxxx xxxxxx všech xxxxxxxxx xxxxxxx jsou xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 xxxxx xx jakékoliv xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx za 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx za 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxxx x xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že abnormální xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (xxxxxxxxx) xx xx výše xxxxxxx xxxxxxxxx dávky.

S4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxxx xxxxx ve xxxxxxx S4.1 x X4.2 jsou Xxxxxxxxxx xxxxx.

Xxxxx zařazené xx xxxx S4.3 a X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx hormonové x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx včetně:

•	2-androstenol (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. ANTIESTROGENNÍ XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX ESTROGENOVÝCH RECEPTORŮ (XXXXX)]

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX RECEPTORU XXXXXXXX XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx aktivin X		•	xxxxxxxxxx xxxxxxxxxx, např.:
•	konkurenty receptoru xxxxxxxx IIB, např.:			- xxxxx xxxxxxxxx nebo xxxxxx xxxxxxx xxxxxxxxxx
	- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031)			- xxxxxxxx xxxxxx myostatin (xxxx. xxxxxxxxxxx, propeptid xxxxxxxxxx)
•	xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), např. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) xxxxxxxx xxxxxx (XX1516, XX501516) x xxxxxxxx Rev-erbɑ , xxxx. SR9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx insulinů

S4.4.3 meldonium

S4.4.4 xxxxxxxxxxxx

X5 DIURETIKA X XXXXXXXXX LÁTKY

ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Specifické xxxxx.

Xxxxxxx xxxxxxxxx a xxxxxxxxx látky, xxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Diuretika, xxxx xxxx.:

xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; furosemid; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx a hydrochlorothiazid; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx intravenózně, xxxx.:

xxxxxxx, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Probenecid;

a xxxxx látky x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

XXXXXXX

• drospirenon; xxxxxxxx; x xxxxxxx oftalmologické xxxxxxxx inhibitorů karboanhydrázy (xxxx. xxxxxxxxxx, xxxxxxxxxxx);

• xxxxxxx xxxxxx xxxxxxxxxxx x zubní anestezii.

POZNÁMKA

Nález xxxxxxxxxxx xxxxxxxx látky xx stanoveným prahovým xxxxxxx: u formoterolu, xxxxxxxxxxx, xxxxxx, efedrinu, xxxxxxxxxxxxx a pseudoefedrinu xx Xxxxxx Sportovce xxxxxxxx nebo případně Xxx Xxxxxxx ve xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx lokálního xxxxxx xxxxxx inhibitoru xxxxxxxxxxxxxx xxxx lokálního xxxxxx xxxxxxxxxxx x xxxxxxxx anestezii), xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx nález (XXX), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx navíc k xx, xxxxx již xxxx udělena xx xxxxxxxxxx nebo jinou xxxxxxxxx látku.

ZAKÁZANÉ METODY

ZAKÁZANÉ XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx v xxxx xxxxx xxxx Xxxxxxxxxxxx x výjimkou xxxxx x M2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX X XXXX X KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx xxxx opětovné xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx heterologní xxxx xxxx produktů x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx x výjimkou xxxxxxxx plazmy xxxx xxxxxx složek Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx odběrovém xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, přenosu xxxx xxxxxxx kyslíku.

Mimo xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x modifikované xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx náhražky na xxxx xxxxxxxxxxx a xxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx intravaskulární xxxxxxxxxx x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. CHEMICKÁ X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx x podvod xx účelem porušit xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx při Xxxxxxxxx kontrole.

Mimo xxxx xxxxxx:

Xxxxxx x/xxxx úprava Xxxxxx, např. xxxxxxxx xxxxxxx xx Vzorku.

M2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více než xxxxxx 100 ml xx 12 hodin xxxxx infuzí xxxxxxxxx xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxxx, chirurgických xxxxxxx xxxx klinických xxxxxxxxxxxxxx xxxxxxxxx.

X3. GENOVÝ X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx nebo xxxxxx xxxxxxx, které xxxxx xxxxxx sekvence xxxxxx x/xxxx xxxxxxx xxxx jakýmkoliv mechanismem. Xx xxxx xxxx xxxxxxxx technologie úprav xxxx, xxxxxxxxx genů x technologie přenosů xxxx.

X3.2. Xxxxxxx normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx x xxxxxxxx xxxxx xxxxxxxxx x X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxx látky x xxxx sekci: kokain x metylendioxymetamfetamin (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

X6.X: XXXXXXXXXXXX STIMULANCIA

•	adrafinil		•	fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, je Xxxxxxxxxxx xxxxxx.

X6.X: SPECIFICKÁ XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, BMPEA)		•	famprofazon		•	oktopamin
•	3-metylhexan-2-amin (1,2-dimetylpentylamin)		•	fenbutrazát		•	oxilofrin (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-dimetylpentylamin, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (parahydroxyamfetamin)		•	fenmetrazin
•	benzfetamin		•	isomethepten		•	fenprometamin
•	katin1)		•	levmetamfetamin		•	propylhexedrin
•	katinon x xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx a ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (metylendioxyamfetamin)
•	etylamfetamin		•	norfenefrin		•	tuaminoheptan
•	etilefrin		•	oktodrin (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx účinky

VÝJIMKY

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx v xxxxxxx xxxxxx xxxxxxx, xxxxxxx, očního xxxx xxxxxx xxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx, fenoxazolin, xxxxxxxxxxx, nafazolin, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2024⁵⁾.

X7 XXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx v této xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx jejich xxxxxxxxxx všech optických xxxxxxx, xxxx. x- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (heroin)		•	metadon		•	oxykodon		•	tramadol
						•	oxymorfon

S8 KANABINOIDY

ZAKÁZANÉ XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx. Xxxxxxxx látky x xxxx sekci: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x xxxxxxxxxx kanabinoidy xxxx zakázané, xxxx.

• x xxxxxx (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• xxxxxxxx a xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx glukokortikoidy xxxx xxxxxxxx, xxxxx xxxx podávány jakoukoliv xxxxxxxx, perorální [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx cestou.

Mimo xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Jiné xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx se xxxxxxxxx x rámci xxxxxxxx xxxxxxxxxxxx dávek x xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X URČITÝCH XXXXXXXX

Xxxxxxx xxxxxxxx xxxxx v xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx v xxxxxxxxxxxxx sportech Xxx Xxxxxxx a xxx xx to xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• lyžování/snowboarding (XXX) – xxxxx xx xxxxxx, xxxxxxxxxxx xxxxx / X-xxxxx x xxxxxxxxx U-rampa / xxx air

• xxxxxxxxxxxx xxxxx (XXX)

• xxxxxxxx xxxxxx (CMAS)* x xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx x xxxxxxx na xxxx

• xxxxxxxx (xxxxxxx disciplíny) (XXXX)

• šipky (XXX)

• xxxx (XXX)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* zakázané také Xxxx xxxxxx

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx jazyce
 

¹⁾ katin (x-xxxxxxxxxxxxxxxx) a jeho x-xxxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx x moči xxxxx xxx 5 xxxxxxxxxx x 1 xx.

²⁾ xxxxxxxxxxxxx: xxxxxxxx pouze xxx koncentraci x xxxx vyšší než 150 mikrogramů v 1 xx.

³⁾ xxxxxxx x xxxxxxxxxxxx: zakázány xxx koncentraci v xxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx.

⁴⁾ xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx podávání, xxxx. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx a xxxxxxxx: xxxx xxxxx xxxx zahrnuté do Xxxxxxxxxxxxxx programu 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx látky.

Informace

Právní xxxxxxx x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.

Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, pokud xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu